Michael G Argenziano
Columbia University in the City of New York
H-index: 7
North America-United States
Top articles of Michael G Argenziano
Microanatomy of Intracranial Human Thrombi by Single Nuclei Transcriptomics
Stroke
2024/2
Influence of preoperative and intraoperative factors on recovery after aortic root surgery
General Thoracic and Cardiovascular Surgery
2024/2
A pharmacological toolkit for human microglia identifies Topoisomerase I inhibitors as immunomodulators for Alzheimer's disease
bioRxiv
2024
Biomarkers Of Immunotherapy In Glioblastoma
2024/4/1
Michael G Argenziano
H-Index: 1
Single-cell analysis of 5-aminolevulinic acid intraoperative labeling specificity for glioblastoma
Journal of Neurosurgery
2023/9/22
No-reflow post-recanalization in acute ischemic stroke: mechanisms, measurements, and molecular markers
2023/9
Michael G Argenziano
H-Index: 1
Re-convolving the compositional landscape of primary and recurrent glioblastoma reveals prognostic and targetable tissue states
Nature Communications
2023/5/4
Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism
Nature Communications
2023/3/2
A cell state specific metabolic vulnerability to GPX4-dependent ferroptosis in glioblastoma
bioRxiv
2023/2/23
Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma
2023/1/1
Michael G Argenziano
H-Index: 1
Biologically-informed deep neural networks provide quantitative assessment of intratumoral heterogeneity in post-treatment glioblastoma
bioRxiv
2022/12/20
EPCO-12. SEX-SPECIFIC PATTERNS CONNECTING LOCOREGIONAL MRI FEATURES AND IMMUNOHISTOCHEMISTRY OF IMAGE-LOCALIZED BIOPSIES OF GLIOBLASTOMA
Neuro-Oncology
2022/11
DDDR-28. EGFR AND SRC-MEDIATED ACTIVATION OF STAT3 DRIVES RESISTANCE TO MITOTIC INHIBITORS IN GLIOBLASTOMA, AND CAN BE REVERSED WITH FDA-APPROVED DRUGS
Neuro-Oncology
2022/11/1
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial
The Lancet Oncology
2022/11/1
Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma
Cell reports
2022/6/21
Michael G Argenziano
H-Index: 1
Jessica Griffith
H-Index: 1
Surabhi Talele
H-Index: 2
Vito Quaranta
H-Index: 32
Thoracic low grade glial neoplasm with concurrent H3 K27M and PTPN11 mutations
Acta Neuropathologica Communications
2022/4/28
Patient characteristics and antiseizure medication pathways in newly diagnosed epilepsy: Feasibility and pilot results using the common data model in a single-center electronic …
Epilepsy & Behavior
2022/4/1
Characterization of Antiepileptic Drug Treatment Pathways with the Common Data Model: Pilot Results from Columbia University Irving Medical Center
2021
Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience
Pharmaceutics
2021
Protein kinase Cι and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities
Cell reports
2021/11/23
Yi Liu
H-Index: 21
Michael G Argenziano
H-Index: 1
Co-Authors
